Drug Database
Back to search

Netherlands· NL-822290ef3d06

Bivalirudine Accord 250 mg poeder voor concentraat voor oplossing voor injectie/infusie

A bivalirudin product containing bivalirudine, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC B01AE06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBivalirudine Accord 250 mg poeder voo…ATCB01AE06REGISTER NO.NL-822290ef3d06PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bivalirudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bivalirudin is registered in 11 of 19 countries.

Countries holding a registration under ATC B01AE06 (bivalirudin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search bivalirudin products by name

Bivalirudin · ATC B01AE06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Polandprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BIVALIRUDINE
Manufacturer
Accord Healthcare B.V.
Country
Netherlands (NL)
ATC code
B01AE06
ATC class
Bivalirudin
Defined daily dose
0.25 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    116622

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

148 interactions on record for bivalirudin.

Graded by severity as the source publishes them — 63 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bivalirudin against other medicinesHow interaction checks work

Bivalirudin · interactions on record

148 records

  • 63 severe
  • 85 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bivalirudin in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bivalirudin products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Bivalirudin Accord
  • Belgium · Bivalirudin Accord Healthcare, Bivalirudin Hikma
  • Germany · Bivalirudin Accord
  • Denmark · Bivalirudin Reig Jofre
  • Spain · Bivalirudina Hikma, Bivalirudina Sala
  • Finland · Bivalirudin Bioglan
  • France · Bivalirudine Accord, Bivalirudine Hikma
  • United Kingdom (Northern Ireland) · Bivalirudin Accord Healthcare, Bivalirudin Kensington Pharma
  • Italy · Bivalirudina Accord, Bivalirudina Hikma
  • Poland · Biwalirudyna Accord
  • Portugal · Bivalirudina Accord, Bivalirudina Hikma
  • Sweden · Bivalirudin Reig Jofre
  • Slovenia · Bivalirudin Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9d11614d-5d33-4af8-b1b1-4c3c1ddb49cd
GET /v1/drugs/9d11614d-5d33-4af8-b1b1-4c3c1ddb49cd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor injectie / infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h116622_smpc.pdf",
  "strength": null,
  "atc_label": "Bivalirudin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg116622",
  "excipients": [
    "MANNITOL (D-) (E 421)",
    "NATRIUMHYDROXIDE (E 524)",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "BIVALIRUDINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h116622.pdf",
  "authorised_at": "2016/07/13",
  "procedure_number": "AT/H/0586/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "116622",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about bivalirudin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console